A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance (RPX2014/RPX7009) in Subjects With Renal Insufficiency

Trial Profile

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance (RPX2014/RPX7009) in Subjects With Renal Insufficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Meropenem/vaborbactam (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions
  • Sponsors Rempex Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top